Original article| Volume 27, ISSUE 5, P326-330, August 2005

Download started.


Comparison of two low dose ACTH therapies for West syndrome: their efficacy and side effect


      In order to clarify the appropriate usage of adrenocorticotropic hormone (ACTH), the efficacy and side effects of two different regimens of low dose ACTH therapy were compared. Thirty-four patients with West syndrome (WS) were treated with ACTH. The dose of synthetic ACTH-Z was 0.015 mg/kg/dose in 18 patients who were treated between 1996 and 1998 (regimen A), and 0.010 mg/kg/dose in 16 patients who were treated between 1999 and 2001 (regimen B). Patients were classified into cryptogenic and symptomatic groups. Efficacy and adverse effects of ACTH were compared between regimens A and B. Similar analyses were performed after stratification into cryptogenic and symptomatic groups. The efficacy of ACTH was not different between regimens A and B. However, among patients with symptomatic WS, the number of ACTH injections and the dose of ACTH until cessation of spasms were significantly smaller in regimen A than in regimen B. There was no significant difference in these variables between the regimens among those with cryptogenic WS. Adverse effects were not different between regimens A and B. 0.010 mg/kg per day of ACTH will be adequate for cryptogenic WS, but 0.015 mg/kg per day of ACTH is recommended for symptomatic WS.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sorel L.
        • Dusaucy-Bauloye A.
        Findings in 21 cases of Gibb's hypsarrhythmia: spectaculare effectiveness of ACTH.
        Acta Neurol Psychiatr Berg. 1958; 58: 130-141
        • Bobele G.B.
        • Bodensteiner J.B.
        The treatment of infantile spasms by child neurologist.
        J Child Neurol. 1994; 9: 432-435
        • Cossette P.
        • Riviello J.J.
        • Carmant L.
        ACTH versus vigabatrin therapy in infantile spasms: a retrospective study.
        Neurology. 1999; 52: 1691-1694
        • Koo B.
        Vigabatrin in the treatment of infantile spasms.
        Pediatr Neurol. 1999; 20: 106-110
        • Riikonen R.
        • Donner M.
        ACTH therapy in infantile spasms: side effects.
        Arch Dis Child. 1980; 55: 664-672
        • Okuno T.
        • Ito M.
        • Konishi Y.
        • Yoshioka M.
        • Nakano Y.
        Cerebral atrophy following ACTH therapy.
        J Comput Assist Tomogr. 1980; 4: 20-23
        • Hara K.
        • Watanabe K.
        • Miyazaki S.
        • Hakamada S.
        • Yamada H.
        • Nakamura S.
        Apparent brain atrophy and subdural hematoma following ACTH therapy.
        Brain Dev. 1981; 3: 45-49
        • Satoh J.
        • Takeshige H.
        • Hara H.
        • Fukuyama Y.
        Brain shrinkage and subdural effusion associated with ACTH administration.
        Brain Dev. 1982; 4: 13-20
        • Shamir R.
        • Garty B.Z.
        • Rachmel A.
        • Kivity S.
        • Alpert G.
        Risk of infection during adrenocorticotropic hormone treatment in infants with infantile spasms.
        Pediatr Infect Dis J. 1993; 12: 913-916
        • Ito M.
        • Miyajima T.
        • Fujii T.
        • Okuno T.
        Subdural hematoma during low-dose ACTH therapy in patients with West syndrome.
        Neurology. 2000; 54: 2346-2347
        • Cotterrell M.
        • Balazs R.
        • Johnson A.L.
        Effects of corticosteroids on the biochemical maturation of rat brain: postnatal cell formation.
        J Neurochem. 1972; 19: 2151-2167
        • Howard E.
        • Benjamins J.A.
        DNA, ganglioside and sulfatide in brains of rats given corticosterone in infancy, with an estimate of cell loss during development.
        Brain Res. 1975; 92: 73-87
        • Winick M.
        • Coscia A.
        Cortisone-induced growth failure in neonatal rats.
        Pediatr Res. 1968; 2: 451-455
        • Ito M.
        • Aiba H.
        • Hashimoto K.
        • Kuroki S.
        • Tomiwa K.
        • Okuno T.
        • et al.
        Low-dose ACTH therapy for West syndrome: initial effects and long-term outcome.
        Neurology. 2002; 58: 110-114
        • Fukuyama Y.
        Infantile spasms.
        in: Hara T. Hirai T. Fukuyama Y. Epilepsy: its clinical and research. Igaku Shoin, Tokyo1974: 164-188 ([In Japanese])
        • Watanabe K.
        Medical treatment of West syndrome in Japan.
        J Child Neurol. 1995; 10: 143-147
        • Kuriyama M.
        • Konishi Y.
        • Fujii Y.
        • Yasujima M.
        • Sudo M.
        • Konishi K.
        • et al.
        Treatment of infantile spasms with long-term low dose ACTH(in Japanese).
        No To Hattatsu (Tokyo). 1992; 24: 469-474
        • Yanagaki S.
        • Oguni H.
        • Hayashi K.
        • Imai K.
        • Funatuka M.
        • Tanaka T.
        • et al.
        A comparative study of high dose and low dose ACTH therapy for West syndrome.
        Brain Dev. 1999; 21: 461-467
        • Watanabe K.
        West syndrome: etiological and prognostic aspects.
        Brain Dev. 1998; 20: 1-8
        • Haga Y.
        • Watanabe K.
        • Negoro T.
        • Aso K.
        • Kito M.
        • Maeda N.
        • et al.
        A study of ACTH dosage for treatment of West syndrome(in Japanese).
        No To Hattatsu (Tokyo). 1993; 25: 215-220